Company will present data from its
successful rejuvenation of fibroblasts and keratinocytes to
influential gathering of international dermatologists
MOUNTAIN
VIEW, Calif., Sept. 4,
2024 /PRNewswire/ -- Turn Biotechnologies, a
developer of novel mRNA medicines and enabling technologies, will
reveal data from its breakthrough cell rejuvenation to participants
of the annual European Society of Dermatological Research (ESDR),
an influential international meeting of dermatologists being held
in Lisbon.
Dr. Edward Hsia,PhD Turn Bio vice president of Dermatology, will
share details about the company's successful reversal of the
effects of aging in fibroblasts by up to 10.4 years – more than
double the previously reported improvement. He will also offer data
from Turn Bio's historic rejuvenation of human keratinocytes, which
comprise 90% of the epidermis. It is the first time anyone has
reported rejuvenation of keratinocytes.
Hsia will present to dermatologists and other skin experts
during a podium presentation at the European Society for
Dermatological Research (ESDR) on Friday,
Sept 6, from 4:30 p.m. to 5:30
p.m. (WEST).
Turn Bio achieved the rejuvenation using its proprietary ERA™
technology to reprogram aged human fibroblasts and keratinocytes.
The rejuvenation effect on treated cells was measured using the
industry standard of epigenetic clocks that estimates cellular age
based on 353 epigenetic markers on the DNA.
Hsia's presentation will be the first time Turn Bio shares its
data with an audience of skin experts.
"Our achievement brings us one step closer to truly personalized
skin rejuvenation, something long sought by dermatologists and
their patients," said Turn Bio CEO Anja
Krammer. "Consumers spend billions annually on skin
treatments and skin care products, demonstrating the importance of
our innovation. We believe healthy skin begins at the cellular
level and our progress promises breakthrough solutions to millions
of people."
ABOUT TURN BIOTECHNOLOGIES
Turn Bio is a pre-clinical-stage company focused on repairing
tissue at the cellular level and developing transformative drug
delivery systems. The company's proprietary mRNA-based ERA™
reprogramming technology restores optimal gene expression by
combatting the effects of aging in the epigenome. This restores
cells' ability to prevent or treat disease and heal or regenerate
tissue. It will help to fight incurable chronic diseases. Its
eTurna™ delivery platform uses unique formulations to precisely
deliver cargo to specific organs, tissues, and cell types.
The company is completing pre-clinical research on tailored
therapies targeting indications in dermatology and immunology, and
developing therapies for ophthalmology, osteo-arthritis, and the
muscular system. For more information, see www.turn.bio.
FOR MORE INFORMATION, CONTACT:
Jim Martinez, rightstorygroup
382721@email4pr.com or (312) 543-9026
View original content to download
multimedia:https://www.prnewswire.com/news-releases/turn-biotechnologies-reports-historic-skin-cell-rejuvenation-breakthroughs-at-esdr-this-week-302238018.html
SOURCE Turn Biotechnologies